tiprankstipranks
Trending News
More News >

US Physical Therapy Reports Strong Q1 2025 Results

Story Highlights
  • U.S. Physical Therapy reported a 16.5% increase in adjusted EBITDA for Q1 2025.
  • The company achieved record patient volume and expanded its clinic network despite challenges.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

US Physical Therapy ( (USPH) ) has issued an update.

U.S. Physical Therapy, Inc. reported strong financial results for the first quarter of 2025, with a 16.5% increase in adjusted EBITDA and a 16.4% rise in total revenue from physical therapy operations compared to the same period in 2024. The company saw record patient volume, with average daily visits per clinic reaching an all-time high, and continued to expand its clinic network through acquisitions and openings, despite challenges such as a Medicare rate reduction.

Spark’s Take on USPH Stock

According to Spark, TipRanks’ AI Analyst, USPH is a Neutral.

US Physical Therapy scores moderately with strengths in revenue growth and strategic acquisitions. However, concerns about net income volatility, rising debt levels, and a bearish technical outlook weigh on the stock. The valuation is on the higher side, which may deter some investors. Recent efforts to enhance operational efficiency and expand through acquisitions are positive, but challenges remain in achieving consistent profitability.

To see Spark’s full report on USPH stock, click here.

More about US Physical Therapy

U.S. Physical Therapy, Inc. is a national operator of outpatient physical therapy clinics and a provider of industrial injury prevention services.

Average Trading Volume: 120,553

Technical Sentiment Signal: Sell

Current Market Cap: $1.09B

For a thorough assessment of USPH stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App